FDA accepts Merck’s suvorexant NDA for standard review

Merck, known as MSD outside the United States and Canada, today announced that the New Drug Application (NDA) for suvorexant, the company's investigational insomnia medicine, has been accepted for standard review by the U.S. Food and Drug Administration (FDA).

Full Story →